Drug intelligence / Profile preview

RTG-2023

Development stage: Preclinical
Lead developer: RetinalGenix Technologies
Modality: Small Molecules
Administration: Ophthalmic

Overview

RTG-2023 is an investigational therapeutic candidate being developed by RetinalGenix Technologies for the treatment of dry age-related macular degeneration (dry AMD). The drug is a repurposed FDA-approved pharmaceutical that acts as an anti-VEGF therapy. RetinalGenix's development strategy for RTG-2023 integrates the drug with a proprietary platform that utilizes high-resolution retinal imaging and pharmacogenetic mapping to guide and stratify treatment for patients with dry AMD. As of late 2023, the company has submitted provisional patent applications for the candidate and is in the preclinical (pre-IND) stage of development, supported by a clinical study involving a cohort of 490 patients to validate its mapping approach.

Targets

VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on RTG-2023.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RTG-2023.

Explore the full profile